Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 22,207 · see citing works

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,262 · see citing works

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,149 · see citing works

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

Bild, A., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D. A. D., Joshi, M.-B., Harpole, D. H., Lancaster, J. M., Berchuck, A., et al. (2005) · Nature · doi:10.1038/nature04296 · Cited by 2,032 · see citing works

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · see citing works

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint

Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,877 · see citing works

RAS oncogenes: weaving a tumorigenic web

Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330 · see citing works

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,329 · see citing works

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · see citing works

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · see citing works

The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

Harrington, L. S., Findlay, G. M., Gray, A., Толкачева, Т. А., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123 · see citing works

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · see citing works

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 862 · see citing works

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works

Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies

Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800 · see citing works

Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing

Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J. M., Guo, J., Johnson, J. M., Lim, L. P., Karpilow, J. M., Nichols, K. E., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 790 · see citing works

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750 · see citing works

Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ

Pacold, M. E., Suire, S., Perišić, O., Lara‐González, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 603 · see citing works

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., Rominger, C. M., Erskine, S. G., Fisher, K. E., Yang, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2200 · Cited by 591 · see citing works

Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice

Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E. L., Stamp, G., Alitalo, K. K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589 · see citing works

Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation.

Rodriguez‐Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., & Downward, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00602.x · Cited by 565 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works

Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation

Tzatsos, A., & Kandror, K. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.63-76.2006 · Cited by 399 · see citing works

The activation of phosphatidylinositol 3-kinase by Ras

Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana Julian Downward, P., & Parker, P. J. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00177-9 · Cited by 329 · see citing works

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R., Rabinovich, B. A., Hann, B. C., Dankort, D. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320 · see citing works

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 299 · see citing works

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

Kumar, M. S., Hancock, D. C., Molina‐Arcas, M., Steckel, M., East, P., Diefenbacher, M. E., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 264 · see citing works

TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

Singh, A., Sweeney, M. F., Yu, M., Burger, A., Greninger, P., Benes, C. H., Haber, D. A., & Settleman, J. (2012) · Cell · doi:10.1016/j.cell.2011.12.033 · Cited by 260 · see citing works

Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils

Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 248 · see citing works

Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer

Chandarlapaty, S. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0018 · Cited by 235 · see citing works

Regulation of phosphoinositide 3-kinase expression in health and disease

Kok, K. B., Geering, B., & Vanhaesebroeck, B. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.01.003 · Cited by 231 · see citing works

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210 · see citing works

SnapShot: Non-Small Cell Lung Cancer

Heist, R. S., & Engelman, J. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.007 · Cited by 196 · see citing works

Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance

Lim, K., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.014 · Cited by 191 · see citing works

Cooperative Activation of PI3K by Ras and Rho Family Small GTPases

Yang, H. W., Shin, M., Lee, S., Kim, J., Park, W. S., Cho, K., Meyer, T., & Heo, W. D. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.007 · Cited by 191 · see citing works

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies

Steckel, M., Molina‐Arcas, M., Weigelt, B., Marani, M., Warne, P. H., Kuznetsov, H. S., Kelly, G. P., Saunders, B., Howell, M. T., Downward, J., et al. (2012) · Cell Research · doi:10.1038/cr.2012.82 · Cited by 171 · see citing works

Immortalization of Human Alveolar Epithelial Cells to Investigate Nanoparticle Uptake

Kemp, S. J., Thorley, A. J., Gorelik, J., Seckl, M. J., O’Hare, M. J., Arcaro, A., Korchev, Y. E., Goldstraw, P. G., & Tetley, T. D. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0334oc · Cited by 146 · see citing works

Activation of Phosphoinositide 3-Kinase γ by Ras

Suire, S., Hawkins, P. T., & Stephens, L. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00933-8 · Cited by 116 · see citing works

The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors

Scagliotti, G. V., & Novello, S. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.008 · Cited by 96 · see citing works

Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation

Dajee, M., Tarutani, M., Deng, H., Cai, T., & Khavari, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205287 · Cited by 94 · see citing works

Selective Raf inhibition in cancer therapy

Khazak, V., Astsaturov, I. A., Serebriiskii, I. G., & Golemis, E. A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1587 · Cited by 80 · see citing works

Emerging MEK inhibitors

McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63 · see citing works

Loss of the tumorigenic phenotype with in vitro, but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an alpha 5/beta 1-integrin-fibronectin interaction.

Schiller, J. H., & BITTNER, G. (1995) · PubMed · Cited by 31 · see citing works

Quantitative model of Ras–phosphoinositide 3-kinase signalling cross-talk based on co-operative molecular assembly

Kaur, H., Park, C. S., Lewis, J. M., & Haugh, J. M. (2005) · Biochemical Journal · doi:10.1042/bj20051022 · Cited by 26 · see citing works

Non-small-cell lung cancers: a heterogeneous set of diseases

Chen, Z., Brainson, C. F., Hammerman, P. S., Kim, C. F., & Wong, K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3775 · Cited by 1,935 · see citing works

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · see citing works

Targeted drug delivery strategies for precision medicines

Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N. X., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,201 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset

Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works

Oncogenic KRAS signalling in pancreatic cancer

Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504 · see citing works

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

Chio, I. I. C., Jafarnejad, S. M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.056 · Cited by 378 · see citing works

CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities

Han, K., Pierce, S. E., Li, A., Spees, K., Anderson, G. R., Seoane, J. A., Lo, Y.-H., Dubreuil, M., Olivas, M., Kamber, R. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2099-x · Cited by 311 · see citing works

Tissue-specific tumorigenesis: context matters

Schneider, G., Schmidt‐Supprian, M., Rad, R., & Saur, D. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.5 · Cited by 312 · see citing works

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · see citing works

Genetics and biomarkers in personalisation of lung cancer treatment

Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 304 · see citing works

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249 · see citing works

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231 · see citing works

Molecular pathways and therapeutic targets in lung cancer

Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220 · see citing works

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203 · see citing works

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

Simpson, A. D., Kamdoum, W. V. P., Macaulay, V. M., Weyer-Czernilofsky, U., & Bogenrieder, T. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0514-5 · Cited by 182 · see citing works

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

Castellano, E., Sheridan, C., Thin, M. Z., Nye, E. L., Spencer‐Dene, B., Diefenbacher, M. E., Moore, C., Kumar, M. S., Murillo, M. M., Gronroos, E. C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.012 · Cited by 184 · see citing works

Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis

Hill, C. N., Li, J., Liu, D., Conforti, F., Brereton, C. J., Yao, L., Zhou, Y., Alzetani, A., Chee, S., Marshall, B. G., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1820-x · Cited by 177 · see citing works

The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link

Bowers, L. W., Rossi, E. L., Oâ€TMFlanagan, C. H., deGraffenried, L. A., & Hursting, S. D. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00077 · Cited by 174 · see citing works

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 162 · see citing works

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer

Kanu, N., Cerone, M. A., Goh, G., Zalmas, L., Bártková, J., Dietzen, M., McGranahan, N., Rogers, R. F., Law, E. K., Gromova, I., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1042-9 · Cited by 165 · see citing works

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i> -Mutant Lung Cancer

Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162 · see citing works

Molecular histology of lung cancer: From targets to treatments

Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.008 · Cited by 161 · see citing works

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies

Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155 · see citing works

Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis

Yao, L., Conforti, F., Hill, C. N., Bell, J., Drawater, L., Li, J., Liu, D., Xiong, H., Alzetani, A., Chee, S., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0175-7 · Cited by 147 · see citing works

ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1

Wang, Y., Bu, F., Royer, C., Serres, S., Larkin, J. R., Soto, M. S., Sibson, N. R., Salter, V., Fritzsche, F. R., Turnquist, C., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3050 · Cited by 146 · see citing works

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma

Yohe, M. E., Gryder, B. E., Shern, J. F., Song, Y., Chou, H.-C., Sindiri, S., Mendoza, A., Patidar, R., Zhang, X., Guha, R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4470 · Cited by 148 · see citing works

PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

Weigelt, B., Warne, P. H., Lambros, M. B. K., Reis-Filho, J. S., & Downward, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3815 · Cited by 138 · see citing works

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 134 · see citing works

Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

Venkatesan, S., Angelova, M., Puttick, C., Zhai, H.-R., Caswell, D. R., Lu, W.-T., Dietzen, M., Galanos, P., Evangelou, K., Bellelli, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0725 · Cited by 134 · see citing works

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

King, H., Aleksic, T., Haluska, P., & Macaulay, V. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.004 · Cited by 132 · see citing works

The Importance of Being PI3K in the RAS Signaling Network

Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 123 · see citing works

The ERBB network facilitates KRAS-driven lung tumorigenesis

Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111 · see citing works

RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Nicolantonio, F. D., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 109 · see citing works

Synthetic Lethal Vulnerabilities in <i>KRAS</i>-Mutant Cancers

Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90 · see citing works

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Jones, R. L., Kim, E. S., Nava-Parada, P., Alam, S. M., Johnson, F. M., Stephens, A. W., Simantov, R., Poondru, S., Gedrich, R., Lippman, S. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0265 · Cited by 95 · see citing works

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Vitiello, P. P., Cardone, C., Martini, G., Ciardiello, D., Belli, V., Matrone, N., Barra, G., Napolitano, S., Della Corte, C., Turano, M., et al. (2019) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-019-1035-0 · Cited by 96 · see citing works

Oncogenic Signaling Alters Cell Shape and Mechanics to Facilitate Cell Division under Confinement

Matthews, H. K., Ganguli, S., Plak, K., Taubenberger, A. V., Win, Z., Williamson, M., Piel, M., Guck, J. R., & Baum, B. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.01.004 · Cited by 94 · see citing works

Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?

Baer, R., Cintas, C., Therville, N., & Guillermet‐Guibert, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.001 · Cited by 81 · see citing works

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics

Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77 · see citing works

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75 · see citing works

Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 74 · see citing works

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

Lee, Y., Wang, Y., James, M. A., Jeong, J. H., & You, M. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22342 · Cited by 73 · see citing works

PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint

Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 71 · see citing works

Drugging the Undruggable: Advances on RAS Targeting in Cancer

Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 73 · see citing works

PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context

Schmit, F., Utermark, T., Zhang, S., Wang, Q., Von, T., Roberts, T. M., & Zhao, J. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323004111 · Cited by 72 · see citing works

Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer

Yang, K., Zhang, W., Zhong, L., Xiao, Y., Sahoo, S., Fassan, M., Zeng, K., Magee, P., Garofalo, M., & Shi, L. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01160-x · Cited by 71 · see citing works

Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest

Foy, R., Crozier, L., Pareri, A. U., Valverde, J. M., Park, B. H., Ly, T., & Saurin, A. T. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.020 · Cited by 75 · see citing works

Targeting KRAS: The Elephant in the Room of Epithelial Cancers

Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 71 · see citing works

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines

Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 68 · see citing works

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells

Kharbanda, A., Rajabi, H. N., Jin, C., Alam, M., Wong, K., & Kufe, D. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2360 · Cited by 65 · see citing works

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Macaulay, V. M., Middleton, M. R., Eckhardt, S., Rudin, C. M., Juergens, R. A., Gedrich, R. W., Gogov, S., McCarthy, S. P., Poondru, S., Stephens, A. W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2218 · Cited by 65 · see citing works

Protein restriction and cancer

Yin, J., Ren, W., Huang, X., Li, T., & Yin, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.03.004 · Cited by 64 · see citing works

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer

Zhao, X., Wang, X., Fang, L., Lan, C., Zheng, X., Wang, Y., Zhang, Y., Han, X., Liu, S., Cheng, K., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.015 · Cited by 63 · see citing works

The effects of mutant Ras proteins on the cell signalome

Takács, T., Kudlik, G., Kurilla, A., Szeder, B., Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09912-8 · Cited by 62 · see citing works

Carcinogenic risk of chromium, copper and arsenic in CCA-treated wood

Ohgami, N., Yamanoshita, O., Thang, N. D., Yajima, I., Nakano, C., Wu, W., Ohnuma, S., & Kato, M. (2015) · Environmental Pollution · doi:10.1016/j.envpol.2015.07.041 · Cited by 62 · see citing works

KRAS induces lung tumorigenesis through microRNAs modulation

Shi, L., Middleton, J. D., Jeon, Y.-J., Magee, P., Veneziano, D., Laganà, A., Leong, H. S., Sahoo, S., Fassan, M., Booton, R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0243-9 · Cited by 60 · see citing works

The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer

Heidegger, I. M., Massoner, P., Sampson, N., & Klocker, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.026 · Cited by 56 · see citing works

KRAS: A Druggable Target in Colon Cancer Patients

Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 55 · see citing works

miR-375 Suppresses IGF1R Expression and Contributes to Inhibition of Cell Progression in Laryngeal Squamous Cell Carcinoma

Luo, J., Wu, J., Li, Z.-H., Qin, H., Wang, B., Wong, T., Yang, W., Fu, Q., & Lei, W. (2014) · BioMed Research International · doi:10.1155/2014/374598 · Cited by 55 · see citing works

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory

Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 54 · see citing works

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies

Liu, Z., Liu, Y., Qian, L., Jiang, S., Gai, X., Ye, S., Chen, Y., Wang, X., Zhai, L., Xu, J. Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.021 · Cited by 54 · see citing works

The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix

Pei, X., Xiang, L., Chen, W., Jiang, W., Yin, L., Shen, X., Zhou, X., & Yang, H. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.019 · Cited by 48 · see citing works

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation

Yamaoka, T., Ohmori, T., Ohba, M., Arata, S., Murata, Y., Kusumoto, S., Andō, K., Ishida, H., Ohnishi, T., & Sasaki, Y. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0482 · Cited by 47 · see citing works

Bidirectional epithelial–mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis

Yao, L., Zhou, Y., Li, J., Wickens, L., Conforti, F., Rattu, A., Ibrahim, F. M., Alzetani, A., Marshall, B. G., Fletcher, S., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101096 · Cited by 47 · see citing works

The role of wild-type RAS in oncogenic RAS transformation

Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42 · see citing works

Update in Lung Cancer 2014

Spira, A. E., Halmos, B., & Powell, C. A. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0756up · Cited by 43 · see citing works

Successes and Limitations of Targeted Cancer Therapy in Lung Cancer

Suda, K., & Mitsudomi, T. (2014) · Progress in tumor research · doi:10.1159/000355902 · Cited by 42 · see citing works

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis

Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38 · see citing works

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R

de Lint, K., Poell, J. B., Soueidan, H., Jastrzebski, K., Rodriguez, J. V., Lieftink, C., Wessels, L. F. A., & Beijersbergen, R. L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0865 · Cited by 40 · see citing works

Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line

Ayub, A., Yip, W. K., & Seow, H. F. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.031 · Cited by 39 · see citing works

Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma

Zhu, Z., Golay, H. G., & Barbie, D. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.108 · Cited by 38 · see citing works

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Wilky, B. A., Rudek, M. A., Ahmed, S. R., Laheru, D. A., Cosgrove, D., Donehower, R. C., Nelkin, B. D., Ball, D. W., Doyle, L. A., Chen, H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.515 · Cited by 37 · see citing works

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 35 · see citing works

Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice

Xiong, H., Yu, H., Zhang, J., Fang, L., Wu, D., Lin, X., & Xie, C. (2023) · Military Medical Research · doi:10.1186/s40779-023-00501-8 · Cited by 35 · see citing works

Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression

Cicchini, M., Buza, E. L., Sagal, K. M., Gudiel, A. A., Durham, A. C., & Feldser, D. M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.069 · Cited by 35 · see citing works

Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing

Hechtman, J. F., Zehir, A., Mitchell, T. N., Borsu, L. A., Singer, S., Tap, W. D., Oultache, A., Ladanyi, M., & Nafa, K. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22230 · Cited by 35 · see citing works

IGF-IR Promotes Prostate Cancer Growth by Stabilizing α5β1 Integrin Protein Levels

Sayeed, A., Fedele, C., Trerotola, M., Ganguly, K. K., & Languino, L. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076513 · Cited by 35 · see citing works

Critical role of oncogenic KRAS in pancreatic cancer (Review).

Liu, J., Ji, S., Liang, C., Qin, Y., Jin, K., Liang, D.-K., Xu, W., Shi, S., Zhang, B., Liu, L., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5196 · Cited by 42 · see citing works

Cancer Treatment in the Genomic Era

Doherty, G. J., Petruzzelli, M., Beddowes, E. J., Ahmad, S. S., Caldas, C., & Gilbertson, R. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011840 · Cited by 34 · see citing works

Oncogenic RAS instructs morphological transformation of human epithelia via differential tissue mechanics

Nyga, A., Muñoz, J. J., Dercksen, S., Fornabaio, G., Uroz, M., Trepat, X., Baum, B., Matthews, H. K., & Conte, V. (2021) · Science Advances · doi:10.1126/sciadv.abg6467 · Cited by 34 · see citing works

Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene

Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 33 · see citing works

IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Huang, F., Han, C. L., Greer, A. L., Hillerman, S. M., Reeves, K. A., Hurlburt, W. W., Cogswell, J. P., Patel, D., Qi, Z., Fairchild, C. A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0794-t · Cited by 29 · see citing works

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 28 · see citing works

Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling

Gao, S., Bajrami, I., Verrill, C. L., Kigozi, A., Ouaret, D., Aleksic, T., Asher, R. G., Han, C., Allen, P. W., Bailey, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0806 · Cited by 27 · see citing works

Copper-enriched automotive brake wear particles perturb human alveolar cellular homeostasis

Parkin, J., Dean, L. S. N., Bell, J. A., Easton, N. H. C., Edgeway, L. J., Cooper, M. J., Ridley, R. A., Conforti, F., Wang, S., Yao, L., et al. (2025) · Particle and Fibre Toxicology · doi:10.1186/s12989-024-00617-2 · Cited by 26 · see citing works

Inhibiting the RAS–PI3K Pathway in Cancer Therapy

Sheridan, C., & Downward, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00005-6 · Cited by 25 · see citing works

Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures

Rydzewski, N. R., Peterson, E. R., Lang, J. M., Yu, M., Chang, S. L., Sjöström, M., Bakhtiar, H., Song, G., Helzer, K. T., Bootsma, M. L., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00239-z · Cited by 25 · see citing works

Ablation of insulin receptor substrates 1 and 2 suppresses Kras -driven lung tumorigenesis

Xu, H., Lee, M.-S., Tsai, P.-Y., Adler, A., Curry, N. L., Challa, S. P., Freinkman, E., Hitchcock, D. S., Copps, K. D., White, M. F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718414115 · Cited by 24 · see citing works

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase

van Veen, J. E., Scherzer, M. T., Boshuizen, J., Chu, M., Liu, A., Landman, A. S., Green, S., Trejo, C. L., & McMahon, M. (2019) · eLife · doi:10.7554/elife.43668 · Cited by 21 · see citing works

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Sasaki, K., Yamauchi, T., Semba, Y., Nogami, J., Imanaga, H., Terasaki, T., Nakao, F., Akahane, K., Inukai, T., Verhoeyen, E., et al. (2021) · Blood · doi:10.1182/blood.2021012976 · Cited by 21 · see citing works

R-loop modulated epigenetic regulation in T helper cells mechanistically associates coronary artery disease and non-small cell lung cancer

Rakshit, S., Sunny, J. S., George, M., Hanna, L. E., & Sarkar, K. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101189 · Cited by 21 · see citing works

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Hebron, K. E., Wan, X., Roth, J. S., Liewehr, D. J., Sealover, N. E., Frye, W. J. E., Kim, A., Stauffer, S., Perkins, O. L., Sun, W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1646 · Cited by 19 · see citing works

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Macaya, I., Román, M., Welch, C., Entrialgo‐Cadierno, R., Salmón, M., Santos, A., Feliu, I., Kovalski, J. R., López, I., Rodríguez‐Remírez, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41828-z · Cited by 21 · see citing works

Clinical update on K-Ras targeted therapy in gastrointestinal cancers

Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21 · see citing works

GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence

Chen, W., Chen, Z., Zhang, M., Tian, Y., Liu, L., Lan, R., Zeng, G., Fu, X., Ru, G., Liu, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00824 · Cited by 20 · see citing works

The RalGEF/Ral Pathway

Cooper, J. M., Bodemann, B. O., & White, M. A. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00006-8 · Cited by 20 · see citing works

Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells

Pal, S., Shankar, B. S., & Sainis, K. B. (2013) · Cytokine · doi:10.1016/j.cyto.2013.07.029 · Cited by 20 · see citing works

to Activation of PI3 Kinase in KRAS-Mutant Lung Cancer

Molina‐Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013)

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013;3:548–63

Molina‐Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2016)

Abstract 2987: Identification of new combination therapies for lung tumors harboring KRAS mutations

Molina‐Arcas, M., Moore, C., Rana, S., van Maldegem, F., Horswell, S. D., Hancock, D. C., & Downward, J. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2987

15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations

Molina‐Arcas, M., Moore, C., Rana, S., van Maldegem, F., Horswell, S. D., Hancock, D. C., & Downward, J. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-eacr25.15 · Cited by 1 · see citing works

Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS-Mutant Lung Cancer

Ron, C., & Sweet-Cordero, A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0128 · Cited by 12 · see citing works